|To determine if a patient with cancer and chronic anemia is likely to respond to erythropoietin (EPO) therapy.|
|Hematology, Gynecological Oncology, Hematology/Oncology, Medical Oncology, Pediatric Hematology/Oncology, Hematology|
|administration, response to therapy, adverse effects, drug levels|
|C00-D49, D55-D59, D60-D64, D63|
Patients with anemia may develop a chronic anemia that impacts the quality of life, and some of these patients may benefit from administration of recombinant erythropoietin. Ludwig et al identified factors indicating the likelihood of response to erythropoietin administration. The authors are from Vienna and Graz in Austria.